Catalyst Pharmaceuticals Gets FDA OK for Firdapse in Children
September 29 2022 - 11:59AM
Dow Jones News
By Colin Kellaher
Catalyst Pharmaceuticals Inc. on Thursday said the U.S. Food and
Drug Administration approved the expanded use of its Firdapse
treatment for Lambert-Eaton myasthenic syndrome to include
children.
The Coral Gables, Fla., biopharmaceutical company said the drug
is now available for patients ages 6 through 17 with the rare
condition, in which the immune system attacks the neuromuscular
junctions.
In 2018, the FDA approved Firdapse for adults with Lambert-Eaton
myasthenic syndrome.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 29, 2022 11:44 ET (15:44 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.